These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 39012601)

  • 1. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.
    Woodward EA; Wang E; Wallis C; Sharma R; Tie AWJ; Murthy N; Blancafort P
    Methods Mol Biol; 2024; 2842():267-287. PubMed ID: 39012601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic Editing.
    Sarno F; Koncz M; Eilers RE; Verschure PJ; Rots MG
    Methods Mol Biol; 2024; 2842():289-307. PubMed ID: 39012602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
    Goubert D; Koncz M; Kiss A; Rots MG
    Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
    Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
    Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
    Rahman MM; Tollefsbol TO
    Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer.
    Liu C; Wang N; Luo R; Li L; Yang W; Wang X; Shen M; Wu Q; Gong C
    Theranostics; 2021; 11(20):9833-9846. PubMed ID: 34815789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-based epigenome editing: mechanisms and applications.
    Fadul SM; Arshad A; Mehmood R
    Epigenomics; 2023 Nov; 15(21):1137-1155. PubMed ID: 37990877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
    Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
    Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing CRISPR System for Transcriptional Activation.
    Chen M; Qi LS
    Adv Exp Med Biol; 2017; 983():147-157. PubMed ID: 28639197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on CRISPR/Cas-based epigenetic regulation in plants.
    Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
    Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.
    Naeem M; Majeed S; Hoque MZ; Ahmad I
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible CRISPR-dCas9 Transcriptional Systems for Sensing and Genome Regulation.
    Wu H; Wang F; Jiang JH
    Chembiochem; 2021 Jun; 22(11):1894-1900. PubMed ID: 33433941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new method for the robust expression and single-step purification of dCas9 for CRISPR interference/activation (CRISPRi/a) applications.
    Pandey H; Yadav B; Shah K; Kaur R; Choudhary D; Sharma N; Rishi V
    Protein Expr Purif; 2024 Aug; 220():106500. PubMed ID: 38718989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.